all report title image
  • Published On : Sep 2022
  • Code : CMI5258
  • Industry : Pharmaceutical
  • Pages : 156
  • Formats :

Β-catenin is a multifunctional protein that is essential for preserving physiological homeostasis. A variety of illnesses, including cancer, are caused by its aberrantly high expression. The human equivalent of the drosophila armadillo gene is called β-catenin. It serves as an adapter protein for intracellular adhesion as well as a transcriptional co-regulator.

Global beta catenin market is estimated to be valued at US$ 2,492.0 million in 2022 and is expected to exhibit a CAGR of 9.6 % during the forecast period (2022-2030).

Figure 1.Global Beta Catenin Market Share (%) in Terms of Value, by Type, 2022

Beta Catenin  | Coherent Market Insights

Rise in the incidence of genetic disorders is expected to drive growth of the beta catenin market.

Rise in the incidence of genetic disorders is expected to drive growth of the beta catenin market. For instance, according to data published on May 2022, by Centers for Disease Control and Prevention (CDC), Sickle Cell Disease (SCD) affects approximately 100,000 Americans every year.

CMI table icon

Beta Catenin Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2022: US$ 2,492.0 Mn
Historical Data for: 2017-2020 Forecast Period: 2022 to 2030
Forecast Period 2022 to 2030 CAGR: 9.6 % 2030 Value Projection: US$ 5,201.5 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Type: BBI-801, Exisulind, M-101, Nefopam Hydrochloride, Others
  • By Application: Dermatology, Oncology, Genetic Disorder, Others
Companies covered:

Boston Biomedical Inc, Dicerna Pharmaceuticals Inc., Marina Biotech Inc., Propanac Biopharma Inc, Warp Drive Bio Inc., prism pharma co ltd, , aileron therapeutics inc, MD2 Biosciences Inc, WntRx Pharmaceuticals Inc, Sapience Therapeutics Inc, and Venn Therapeutics LLC

Growth Drivers:
  • Increasing number of genetic disorders
  • Increase in approval of gene therapies
Restraints & Challenges:
  • High cost involved in the treatment of cancer

Figure 2. Global Beta Catenin Market Share (%), By Region, 2022

Beta Catenin  | Coherent Market Insights

Increase in approval of gene therapies drugs is expected to drive the market growth during the forecast period.

Increase in approval of gene therapies drugs is expected to drive the market growth during the forecast period. For instance, in May 2019, the U.S Food and Drug Administration (FDA) approved Zolgensma, for the treatment of pediatric patients less than two years of age with a specific type of spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene.

Global Beta Catenin Market– Impact of Coronavirus (COVID-19) Pandemic

COVID-19 has created significant difficulties for the world economy in addition to placing a great deal of strain on the medical system. COVID-19 has created significant difficulties for the world economy in addition to placing a significant amount of strain on the medical system. Due to the effect on different diagnoses, therapies, and research and development that were all focused on working for COVID-19, the catenin beta market was impacted. Catenin beta demand was lower than the catenin beta market's revenue, which also decreased. the COVID-19 pandemic due to the catenin beta market's use in a number of medical fields, such as dermatology, oncology, and genetic disorders for the treatment of various diseases as well as in the development of a number of medications.

Global Beta Catenin Market: Restraint

The major factors that are expected to hinder growth of the global beta catenin market include high cost involved in the treatment of cancer. For instance, according to data published on April 2022, by National Cancer Institutewhich is the federal government's principal agency for cancer research and training, states that  the average cost of medical care and drugs can cost up to US $42,000 in the year following a cancer diagnosis. Some treatments can exceed $1 million.

Key Players

Major players operating in the global beta catenin market include Boston Biomedical Inc, Dicerna Pharmaceuticals Inc., Marina Biotech Inc.,Propanac Biopharma Inc, Warp Drive Bio Inc.,prism pharma co ltd,aileron therapeutics inc, MD2 Biosciences Inc,WntRx Pharmaceuticals Inc, Sapience Therapeutics Inc, and Venn Therapeutics LLC.

A protein called beta-catenin is crucial for growth and development of embryos. The CTNNB1 gene in humans encodes the protein catenin beta. It is a protein with two functions that is also known as beta-catenin 1 and is involved in the control and coordination of cells, gene transcription, and cell adhesion. Additionally, it promotes cell adhesion, which is essential for the development of structures like bones and skin. The activity of genes in cells is regulated in part by beta-catenin. It functions by attaching to certain molecules known as transcription factors, which bind to Deoxyribonucleic acid (DNA) and influence how an embryo grows into a fully formed human being. Additionally, beta catenin regulates cell division and growth (proliferation). B-catenin is a crucial nuclear effector of canonical Wntsignaling in the nucleus and a structural component of cadherin-based adherens junctions. B-catenin structural and signaling imbalance frequently causes sickness and dysfunctional growth linked to metastasis and cancer. The primary effector in the canonical Wnt cascade is B-catenin, which transmits the signal to the nucleus and causes transcription of Wnt-specific genes that regulate cell fate decisions in a variety of cells and organs.

Market Dynamics

Key players operating in market are expected to drive the market growth during the forecast period, owing to increase in cancer patients. For instance, according to data published in January 2022, by the American Cancer Society, in 2022 in the U.S., there are about 106,180 cases of colon cancer. Moreover, according to data published on March 2021, by World Health Organization, states that, in 2020, there were 2.3 million women diagnosed with breast cancer globally and 685 000 deaths globally.

Key features of the study:

  • This report provides in-depth analysis of the global beta catenin market , and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global beta catenin market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Boston Biomedical Inc, Dicerna Pharmaceuticals Inc., Marina Biotech Inc., Propanac Biopharma Inc, Warp Drive Bio Inc., prism pharma co ltd, , aileron therapeutics inc, MD2 Biosciences Inc, WntRx Pharmaceuticals Inc, Sapience Therapeutics Inc, and Venn Therapeutics LLC
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global beta catenin market  report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global beta catenin market

Detailed Segmentation:

  • Global Beta Catenin Market, By Type:
    • BBI-801
    • Exisulind
    • M-101
    • Nefopam Hydrochloride
    • Others
  • Global Beta Catenin Market, By Application:
    • Dermatology
    • Oncology
    • Genetic Disorder
    • Others
  • Global Beta Catenin Market, By Region:
    • North America
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Country
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Boston Biomedical Inc *
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Dicerna Pharmaceuticals Inc.
    • Marina Biotech Inc.
    • Propanac Biopharma Inc.
    • Warp Drive Bio Inc
    • prism pharma co Ltd.
    • aileron therapeutics Inc.
    • MD2 Biosciences Inc.
    • WntRx Pharmaceuticals Inc.
    • Sapience Therapeutics Inc.
    • Venn Therapeutics LLC

“*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

Global beta catenin market size is estimated to be valued at US$ 2,492.0 million in 2022 and is expected to exhibit a CAGR of 9.6 % between 2022 and 2030.
Factors such as increase in the number of genetic disorders & increase in approval of gene therapies are expected to drive the market growth over the forecast period.
North America is expected to hold a major market share during the forecast period.
The major factor hampering growth of the market is high cost involved in the treatment of cancer.
Major players operating in the market include Boston Biomedical Inc, Dicerna Pharmaceuticals Inc., Marina Biotech Inc., Propanac Biopharma Inc, Warp Drive Bio Inc., prism pharma co ltd, , aileron therapeutics inc, MD2 Biosciences Inc, WntRx Pharmaceuticals Inc, Sapience Therapeutics Inc, and Venn Therapeutics LLC.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo